12 March 2025 in Communications Biology
Structure-based drug design aims to create active compounds with favorable properties by analyzing target structures. Recently, deep generative models have facilitated structure-specific molecular generation. However, many methods are limited by inadequate pharmaceutical data, resulting in suboptimal molecular properties and unstable conformations. Additionally, these approaches often overlook binding pocket interactions and struggle with selective inhibitor design. To address these challenges, we developed a framework called Coarse-grained and Multi-dimensional Data-driven molecular generation (CMD-GEN). CMD-GEN bridges ligand-protein complexes with drug-like molecules by utilizing coarse-grained pharmacophore points sampled from diffusion model, enriching training data. Through a hierarchical architecture, it decomposes three-dimensional molecule generation within the pocket into pharmacophore point sampling, chemical structure generation, and conformation alignment, mitigating instability issues. CMD-GEN outperforms other methods in benchmark tests and controls drug-likeness effectively. Furthermore, CMD-GEN excels in cases across three synthetic lethal targets, and wet-lab validation with PARP1/2 inhibitors confirms its potential in selective inhibitor design.
23 September 2020 in ChemistrySelect
9 April 2026 in Research Square
Molecular properties are measured under different experimental and representational settings, each capturing a distinct aspect of molecular behavior. Integrating such task-dependent molecular information remains challenging, especially when labeled data are scarce and structurally similar molecules exhibit markedly different properties. Here we introduce ArcMol, a task-adaptive framework for molecular property prediction that combines explicit physicochemical descriptors with learned molecular representations. ArcMol organizes these features in a hyperspherical latent space, where molecular similarity is defined by angular relationships. Across more than 150 molecular property prediction benchmarks, ArcMol achieves performance comparable to state-of-the-art methods, while showing improved robustness in low-data settings and for structurally similar molecules. Analyses of the learned representations reveal task-relevant separation, ordered property gradients, and coherent local neighborhoods. We demonstrate ArcMol in a real-world application targeting the kinase IRAK4, where it prioritizes candidate molecules for drug repurposing and leads to the identification of nanomolar type II inhibitors. These results suggest ArcMol as a general framework for molecular property prediction in discovery settings.